“The present problem has uncovered some structural weaknesses while in the EU’s medicines provide chain plus a large dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides claimed. She advisable that provide chain problems be addressed in an EU pharmaceutical approach expected to generally be launched